Form 4: AIM ImmunoTech CEO Acquires 83,334 Shares at $0.12
SEC Form 4 Filing
Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., purchased 83,334 shares of common stock at $0.12 per share on March 4, 2025.
Summary
- On March 4, 2025, Thomas K. Equels, the CEO and President of AIM ImmunoTech Inc., acquired 83,334 shares of the company's common stock.
- The purchase price was $0.12 per share.
- Following this transaction, Equels directly owns 1,764,029 shares of AIM ImmunoTech Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase could indicate confidence, but it's a single transaction and requires further context.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about the company's prospects.
Industry Context
Insider buying is often watched by investors as a signal of management's confidence in the company's future prospects. However, it's important to consider the size of the purchase relative to the insider's existing holdings and the overall market capitalization of the company.
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive sign.
- The purchase could potentially influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of transaction: Thomas K. Equels acquired 83,334 shares of AIM ImmunoTech Inc. common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.